ESMO Congress | Conference

NVL-655 Shows Strong Efficacy in Heavily Pretreated ALK+ NSCLC

September 14th 2024

The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.

Dr Lin on the Efficacy of T-DXd in HER2+ Advanced Breast Cancer With CNS Metastases

September 14th 2024

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

Dr Girard on Nivolumab Plus Relatlimab and Chemotherapy in Stage IV or Recurrent NSCLC

September 14th 2024

Nicolas Girard, MD, discusses the RELATIVITY-104 trial of nivolumab plus relatlimab and chemotherapy in previously untreated stage IV or recurrent NSCLC.

Longer Follow-Up Confirms Superior Outcomes With Amivantamab Plus Chemo in EGFR-Mutant Advanced NSCLC

September 14th 2024

Amivantamab plus chemotherapy yielded promising OS trends compared with chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib.

Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC

September 14th 2024

Treatment with belrestotug plus dostarlimab yielded a clinically meaningful improvement in ORR vs dostarlimab monotherapy in unresectable PD-L1–high NSCLC.

DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets

September 13th 2024

T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.

Tivozanib Monotherapy Bests Lower-Dose Tivozanib Plus Nivolumab in Metastatic RCC

September 13th 2024

The addition of nivolumab to tivozanib did not improve outcomes in metastatic RCC and 1.34 mg of tivozanib monotherapy may be considered as a second-line therapy.

Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC

September 13th 2024

BMS-986012 plus nivolumab and chemotherapy provided a modest PFS benefit but signals of OS improvement in extensive-stage small cell lung cancer.

Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC

September 13th 2024

Belzutifan improved PFS and ORR but failed to deliver a significant improvement in OS vs everolimus in pretreated advanced clear cell renal cell carcinoma.

Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma

September 13th 2024

Breelyn Wilky, MD, discusses updated findings from a phase 1 study investigating botensilimab plus balstilimab in refractory metastatic sarcoma.

Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCC

September 13th 2024

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

Consolidation Durvalumab Shows Consistent Survival Benefit in LS-SCLC Regardless of Prior PCI and CRT Components

September 13th 2024

Consistent survival benefit was seen with consolidation durvalumab across subgroups in the ADRIATIC trial affirms its use as a standard of care in LS-SCLC.

Adjuvant Durvalumab Fails to Boost DFS in Resected NSCLC, Irrespective of PD-L1 Status

September 13th 2024

Adjuvant durvalumab did not provide a disease-free survival advantage over placebo in patients with NSCLC across different PD-L1 subgroups.

Sacituzumab Govitecan Plus Enfortumab Vedotin Shows Early Promise in Metastatic Urothelial Carcinoma

October 31st 2023

Combining sacituzumab govitecan-hziy and enfortumab vedotin-ejfv was safe, feasible, and produced high and early response rates in patients with treatment-resistant metastatic urothelial cancer.

Exploratory Analyses Show Trastuzumab Deruxtecan Elicits Consistent Intracranial Responses in HER2-Mutated NSCLC With Brain Metastases

October 27th 2023

Pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials showed that different doses of fam-trastuzumab deruxtecan-nxki elicited similar intracranial responses in patients with HER2-mutated non–small cell lung cancer who had treated or untreated brain metastases at baseline.

Datopotamab Deruxtecan Elicits Antitumor Activity in Pretreated NSCLC With Actionable Genomic Alterations

October 26th 2023

Datopotamab deruxtecan elicited encouraging responses in patients with heavily pretreated non–small cell lung cancer harboring actionable genomic alterations.

TAR-200 Monotherapy Is Effective and Well Tolerated in BCG-unresponsive NMIBC

October 24th 2023

The intravesical chemotherapy delivery system TAR-200 provided sustained and durable responses in patients with Bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer.

Amivantamab With or Without Lazertinib Extends PFS in EGFR+ Advanced NSCLC After Progression on Osimertinib

October 23rd 2023

Patients with EGFR-mutated advanced non–small cell lung cancer who experienced disease progression after treatment with osimertinib experienced a progression-free survival benefit with amivantamab plus chemotherapy with or without lazertinib compared with chemotherapy alone.

Dr McArthur on Neoadjuvant Pembrolizumab Plus Chemotherapy in ER+/HER2– Breast Cancer

October 23rd 2023

Heather Lynn McArthur, MD, MPH, discusses the primary results from the phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab plus chemotherapy in early-stage, high-risk, estrogen receptor–positive, HER2-negative breast cancer.

Dato-DXd Significantly Improves PFS in Select Subsets of Advanced/Metastatic NSCLC

October 23rd 2023

The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit.